Navigation Links
Vical Licensee Sanofi-aventis Initiates Phase 3 Trial to Reduce Amputations
Date:9/20/2007

SAN DIEGO, Sept. 20 /PRNewswire-FirstCall/ -- Sanofi-aventis, a licensee of Vical Incorporated (Nasdaq: VICL), announced on Monday the initiation of a 500-patient Phase 3 clinical trial of its NV1FGF angiogenesis therapy, which is based on Vical's non-viral DNA delivery technology. Assuming successful completion of the trial, called TAMARIS, sanofi-aventis expects to file for marketing approval in 2010.

The plasmid DNA (pDNA) therapy encodes Fibroblast Growth Factor 1 (FGF-1), a growth factor that stimulates the growth of blood vessels, and is intended to reduce the need for amputations in patients suffering from critical limb ischemia. Sanofi-aventis previously reported results from a Phase 2 trial in 107 patients demonstrating a statistically significant reduction in the rate of both major amputations and all amputations in patients receiving NV1FGF compared with those receiving placebo.

"In addition to DNA vaccines for infectious diseases and cancer, angiogenesis is among the most promising applications of our DNA delivery technology," said Vijay B. Samant, Vical's President and Chief Executive Officer. "The ability of pDNA to induce production of a protein locally at the site of injection ideally matches the desired treatment profile for critical limb ischemia, and perhaps for earlier stages of peripheral vascular disease. We are pleased that sanofi-aventis, one of our two partners in this field, has advanced into Phase 3 testing of this novel therapy addressing a major unmet medical need, and we look forward to successful completion of the trial."

The TAMARIS study is a double-blind, placebo-controlled Phase 3 trial in approximately 500 patients with critical limb ischemia. Four doses of 4 mg ea
'/>"/>

SOURCE Vical Incorporated
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Vaccine Can Prevent Cervical Cancer and Precancerous Lesions
2. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
3. Vical Licensee AnGes MG Announces Positive Results of Phase 3 Angiogenesis Trial in Japan
4. Vical Interim Clinical Results Demonstrate Safety and Tolerability of Inovio Biomedicals Electroporation DNA Delivery Technology
5. Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides Sustained Immune Response in 100 Percent of Women up to 55 Years of Age
6. Vicals Vaxfectin Adjuvant With Needle-free Delivery Enhances DNA Vaccine Performance; Yields Antibody Responses Comparable to Electroporation Without Tolerability Issues
7. New England Journal of Medicine Publishes New Data on Gardasil, Mercks Cervical Cancer Vaccine
8. Cervarix, GSK Cervical Cancer Candidate Vaccine, Demonstrates 100 Percent Protection Against Precancerous Lesions Caused By Cancer-Causing Human Papillomavirus Types 16 & 18 for More Than Five Years
9. Vicals Vaxfectin Adjuvant Achieves Dose-Sparing Effect With Seasonal Influenza Vaccine
10. Nventa Announces Presentation of Positive HspE7 Data from NCI-Sponsored Clinical Trial in Cervical Dysplasia
11. Geron Corp. Licensee TA Sciences Announces Landmark 7/07/07 Teleconference to Answer Questions About TA-65, Their Telomerase Activator With Proven Age Management Benefits
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2015)... PHILADELPHIA , April 24, 2015  Lannett Company, ... has amended and increased its five-year revolving credit facility ... includes an accordion feature that will allow the company ... an additional $30.0 million, subject to securing additional commitments ... date of the credit facility remains December 18, 2018. ...
(Date:4/24/2015)... Mass. , April 24, 2015  Blueprint ... BLU-554, a selective and potent inhibitor of fibroblast ... activity in models of hepatocellular carcinoma (HCC) that ... therapeutic candidate, BLU-554 induced complete tumor regression in ... an FGFR4-activating ligand at the highest dose levels. ...
(Date:4/23/2015)... , April 23, 2015 Once again, ... strengthening our commitment to patient safety. BeaconMedaes, ... fight against infectious disease. The next generation ... Medical gas sensors are now mounted in the assembly, ... need to open ceiling tiles potentially releasing dust spores ...
Breaking Medicine Technology:Lannett Expands Revolving Credit Facility To $120 Million 2Blueprint Medicines Presents New Preclinical Data Demonstrating Its Drug Candidate BLU-554 Induces Significant Tumor Regression in Models of Hepatocellular Carcinoma 2Blueprint Medicines Presents New Preclinical Data Demonstrating Its Drug Candidate BLU-554 Induces Significant Tumor Regression in Models of Hepatocellular Carcinoma 3BeaconMedaes launches new Zone Valve Box Assembly 2
... REDWOOD CITY, Calif., Aug. 17 Cardica, Inc. (Nasdaq: ... Intuitive Surgical, Inc. have entered into a license agreement ... intellectual property, which relates to tissue cutting, stapling and ... to the license agreement, Cardica and Intuitive may also ...
... (Nasdaq: BMRN ) announced today that it ... company developing enzyme replacement therapies (ERT) for the treatment ... ZC-701, a novel fusion of insulin-like growth factor 2 ... Under the terms of the agreement, BioMarin ...
Cached Medicine Technology:Cardica and Intuitive Surgical Enter Into License Agreement 2Cardica and Intuitive Surgical Enter Into License Agreement 3BioMarin Acquires ZyStor Therapeutics, Inc. 2BioMarin Acquires ZyStor Therapeutics, Inc. 3BioMarin Acquires ZyStor Therapeutics, Inc. 4BioMarin Acquires ZyStor Therapeutics, Inc. 5
(Date:4/24/2015)... 2015 Anchor Health Administrators (Anchor), specialists ... today announced their exclusive agreement with LTC Solutions for ... Insurance distribution partner. , Anchor has more than 18 ... benefits for associations, and is currently the designated advocate ... Term Care Insurance member benefit. , “I am very ...
(Date:4/24/2015)... Olive Fertility Centre is proud to ... co-director, has been honoured for his pioneering work in ... Hope Gala. , “We are very pleased to ... has been at the forefront of fertility research and ... Executive Director of Fertile Futures--a Canadian non-profit organization that ...
(Date:4/24/2015)... With years of experience providing consumer ... to be partnered with a veterinary college where veterinary ... This partnership has brought new payment options for families ... providing an in-house payment plan for many years, the ... to increase financing options available to avoid having to ...
(Date:4/24/2015)... National Access Cannabis (NAC), ... to medical cannabis, is taking a leadership role in ... patients. , NAC is the first to back mdBriefCase ... grant, NAC will be providing 300 healthcare professionals with ... to help Canadians gain safe and responsible access to ...
(Date:4/24/2015)... Opera ” was featured on NewsWatch as part of its ... products available to consumers. Andrew Tropeano, a technology expert and ... viewers how this is the fastest way to surf the ... be in existence. But each web browser is slightly different ... Celebrating their 20th anniversary this year, Opera connects over 350 ...
Breaking Medicine News(10 mins):Health News:Olive Fertility Centre Co-founder, Dr Al Yuzpe, Recognized as a Pioneer in Fertility Preservation 2Health News:University of Missouri Veterinary Medical Teaching Hospital Teams with UGA 2Health News:National Access Cannabis Gives 300 Canadian Healthcare Professionals Access to Medical Cannabis Certificate Program 2Health News:A Web Browser That Connects over 350 Million People was Featured on NewsWatch Television 2
... ValueOptions(R), Inc., the nation,s largest independent behavioral ... entered into an agreement with CareIntegra to provide ... its core product offerings. (Logo: ... CareIntegra and ValueOptions(R) will collaborate to develop and ...
... Va., Jan. 7 CEL-SCI Corporation (NYSE Alternext ... announced today the initiation of a definitive study of ... the long-lasting beneficial effects on animals with the disease. ... a large pharmaceutical company which is evaluating the possibility ...
... ORLEANS, Jan. 7 Jones Walker is pleased to announce ... an Order of the British Crown that has been in ... in the New Orleans office of Jones Walker, was recently ... Hamilton, a Partner in the firm,s Mobile and Washington offices, ...
... Virginia, January 7 Ekahau Inc., a leading,provider ... announced,that after a competitive bid process it was ... to provide the Ekahau Real Time,Location System (RTLS) ... (Logo: http://www.newscom.com/cgi-bin/prnh/20081014/324879-a ) , ...
... shownOAKBROOK TERRACE, Ill., Jan. 7 Even though nurses ... study published in the January 2009 issue of ... shows that nurses often are not included when ... such a hands-on role at the bedside of their ...
... Atlanta-based Billian Publishing, Inc.,owners of Billian,s HealthDATA, announced ... (Logo: http://www.newscom.com/cgi-bin/prnh/20070925/BILLIANSLOGO ) ... founded in 1989 just as the information technology,industry ... Since then, new,and established companies have contracted with ...
Cached Medicine News:Health News:ValueOptions(R) Enters Agreement with CareIntegra to Provide Integrated Health Services 2Health News:CEL-SCI Launches Study to Determine Long Lasting Beneficial Effects of its Rheumatoid Arthritis Vaccine 2Health News:CEL-SCI Launches Study to Determine Long Lasting Beneficial Effects of its Rheumatoid Arthritis Vaccine 3Health News:Jones Walker Attorneys Named to Positions in Order of British Crown 2Health News:Ekahau Selected to Provide RTLS to University HealthSystem Consortium 2Health News:Ekahau Selected to Provide RTLS to University HealthSystem Consortium 3Health News:Study Finds Failure to Include Nurses in Process of Admitting Errors to Patients, Families 2Health News:Study Finds Failure to Include Nurses in Process of Admitting Errors to Patients, Families 3Health News:Billian Publishing, Inc. Announces Acquisition of Porter Research 2
Stainless steel construction to withstand sterilization modalities (EtO, Steris, and Sterrad) Wide angle of view...
ENDOlap™ laparoscopes provide excellent image linearity and flatness of field....
Superior imaging through a 410,000 pixel CCD, unseen color replication from a digital signal processor in the scope, and the added benefit of four way tip deflection make the TF410 a superior choice ...
The edge-to-edge clarity of the laparoscopes provides excellent image definition.Even small structures are easily recognized due to the optimal depth of focus. The outstanding optical quality provide...
Medicine Products: